This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Women's Health  • Women's Health, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Monosomy X, or Turner syndrome (TS), affects approximately 1 in 2000 live female births. Most individuals with TS experience ovarian failure at an early age and require estrogen therapy (ET) to induce and maintain feminization. Estrogen is also required for girls and young women to build and maintain good skeletal mineralization. During the course of our TS natural history protocol conducted at the National Institutes of Health Clinical Research Center, Bethesda, Md, we have surveyed women with TS aged 18 to 50 years regarding current estrogen use. There were 20 to 30 new study subjects in this age group who enrolled in the study in each of the calendar years from 2001 to 2005. The survey results are given in the Table.

Table appears in full text version. Table. Decreasing Estrogen Use, 2001-2005

From 2001 to 2004, approximately 90% of study subjects aged 18 to 50 years were receiving ET. Those not receiving ET tended . . . [Full Text of this Article]

AUTHOR INFORMATION
Carolyn A. Bondy, MD; Irene Ceniceros, MS; Eileen Lange, RN, MS; Vladimir K. Bakalov, MD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-term hormone replacement therapy preserves bone mineral density in Turner syndrome
Cleemann et al.
Eur J Endocrinol 2009;161:251-257.
ABSTRACT | FULL TEXT